Radius Health, Inc.

Informe acción NasdaqGM:RDUS

Capitalización de mercado: US$480.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Radius Health Dirección

Dirección controles de criterios 2/4

Información clave

G. Martin

Chief Executive Officer (CEO)

US$3.5m

Compensación total

Porcentaje del salario del CEO17.17%
Permanencia del CEO2.3yrs
Participación del CEOn/a
Permanencia media de la direcciónless than a year
Promedio de permanencia en la Junta Directiva6.8yrs

Actualizaciones recientes de la dirección

No hay actualizaciones

Recent updates

Seeking Alpha • Mar 14

Radius Recycling's Surge Justifies A Reevaluation

Summary Radius Recycling, Inc. shares surged after agreeing to a $30 per share buyout by Toyota Tsusho, offering a 115% premium over the closing price. Despite operational challenges and declining revenues, the buyout provides a significant 77.8% upside since my “buy” rating in June last year. Toyota Tsusho's acquisition reflects their strategic interest in metals recycling, but they assume all risks amid potential market recovery and volatility. Given the substantial premium and limited future upside, I recommend downgrading RDUS stock to a “hold” to align with broader market performance expectations. Read the full article on Seeking Alpha
Seeking Alpha • Feb 25

Radius Recycling Will Benefit From Steel Tariffs

Summary Radius Recycling's profitability is poised to improve due to rising domestic steel prices driven by tariffs, which will increase scrap steel prices and expand margins. Despite historical underperformance, the company's margins will benefit from higher scrap prices without significant cost increases, making it a speculative buy. Monitoring scrap steel prices before Radius's next earnings report could reveal an undervalued stock if the market hasn't yet recognized this linkage. Investing in Radius should be modest, as its viability heavily relies on the continuation of steel tariffs boosting scrap prices. Read the full article on Seeking Alpha
Seeking Alpha • Jul 16

Radius Recycling Stays In The Scrap Pile

Summary Radius Recycling experienced a significant decline in share price, hitting a 52-week low of $12.72. The company is implementing strategic changes to boost profits, including upgrades to non-ferrous scraping capabilities and cost reduction initiatives. Economic indicators such as durable goods orders, average vehicle age, and Chinese steel export production will impact Radius Recycling's business in the near future. Read the full article on Seeking Alpha
Seeking Alpha • Jun 03

Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future

Summary Radius Recycling, Inc. is a large recycler of ferrous and nonferrous metal, with operations in metals recycling, auto parts stores, and steel manufacturing. The company's financial performance has been volatile due to fluctuating steel prices, but its stock is trading at low multiples. Despite short-term challenges, the long-term potential of the recycling industry makes Radius Recycling a cheap business worth considering. Read the full article on Seeking Alpha
Seeking Alpha • Aug 11

Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype

The U.S. Food and Drug Administration (FDA) granted priority review to Menarini's application seeking approval of elacestrant to treat patients with ER+/HER2- advanced or metastatic breast cancer. The FDA accepted the Italian pharmaceutical and diagnostic company's new drug application (NDA) and is expected to make a decision by Feb. 17, 2023. Under priority review, the FDA's goal is to take action within six months, compared to 10 months under standard review. The NDA was backed by data from a phase 3 trial called EMERALD, which was conducted by Radius Health (NASDAQ:RDUS).  Menarini had obtained global licensing rights for elacestrant from Radius in July 2020. Menarini noted that it had filed for approval of the drug in the EU in July 2022. Elacestrant had received the FDA's fast track designation in 2018. RDUS +5.56% to $10.64 premarket Aug. 11
Seeking Alpha • Feb 24

Reevaluating Radius Health

Radius Health, Inc. has lost over half its value since the transdermal patch version of its approved osteoporosis therapy (TYMLOS) flunked a Phase 3 trial in December 2021. Its other late-stage asset (elacestrant) just passed a Phase 3 study for breast cancer, but revenue from it will be muted since it divested its developmental and commercial rights to. Some recent small wins for subcutaneously injected TYMLOS, a soon-to-be-investigated CBD asset, and recent beneficial owner buying merited a deeper dive. A full investment analysis follows in the paragraphs below.
Artículo de análisis • Feb 23

When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?

We feel now is a pretty good time to analyse Radius Health, Inc.'s ( NASDAQ:RDUS ) business as it appears the company...
Artículo de análisis • Jan 01

How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?

It is doubtless a positive to see that the Radius Health, Inc. ( NASDAQ:RDUS ) share price has gained some 58% in the...

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de G. Martin en comparación con los beneficios de Radius Health?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2022n/an/a

-US$69m

Mar 31 2022n/an/a

-US$73m

Dec 31 2021US$3mUS$600k

-US$70m

Sep 30 2021n/an/a

-US$76m

Jun 30 2021n/an/a

-US$60m

Mar 31 2021n/an/a

-US$87m

Dec 31 2020US$12mUS$413k

-US$109m

Compensación vs. Mercado: La compensación total de G.($USD3.49M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.59M).

Compensación vs. Ingresos: La compensación de G. ha sido consistente con los resultados de la empresa en el último año.

CEO

G. Martin (63 yo)

2.3yrs
Permanencia
US$3,493,881
Compensación

Mr. G. Kelly Martin has been Executive Chairman of Wren Therapeutics Ltd. since 2018. Mr. Martin serves as the Chief Executive Officer, President and Director at Radius Health, Inc. since April 28, 2020.H...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
G. Martin
CEO, President & Director2.3yrsUS$3.49msin datos
Danielle Holtschlag
VP of Sales & Head of U.S. Sales Channelsless than a yearUS$741.78ksin datos
Chhaya Shah
Senior VP & Chief Business Officer2.2yrsUS$1.22m0.27%
$ 1.3m
Stavros Manolagas
Founder & Member of the Scientific Advisory Boardno datasin datossin datos
John Potts
Founder & Member of the Scientific Advisory Boardno datasin datossin datos
Michael Rosenblatt
Founderno datasin datossin datos
John Katzenellenbogen
Founder & Member of the Scientific Advisory Boardno datasin datossin datos
Mark Conley
VP, CFOless than a yearsin datossin datos
Peter Schwartzman
Head of Corporate Financeno datasin datossin datos
Ethan Holdaway
Head of Investor Relationsless than a yearsin datossin datos
Kim Clarke
General Counselless than a yearsin datossin datos
Rohan Lathia
Head of Corporate & Business Developmentless than a yearsin datossin datos
0.8yrs
Permanencia media
61.5yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de RDUS no se considera experimentado ( 0.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
G. Martin
CEO, President & Director2.3yrsUS$3.49msin datos
Stavros Manolagas
Founder & Member of the Scientific Advisory Boardno datasin datossin datos
John Potts
Founder & Member of the Scientific Advisory Boardno datasin datossin datos
Michael Rosenblatt
Founderno datasin datossin datos
John Katzenellenbogen
Founder & Member of the Scientific Advisory Boardno datasin datossin datos
Jean-Pierre Garnier
Independent Director6.7yrsUS$544.81k0.045%
$ 215.1k
Sean Murphy
Independent Director2yrsUS$534.84k0.012%
$ 55.5k
Willard Dere
Independent Director7.8yrsUS$536.69k0.037%
$ 178.7k
Cecil Richard Lyttle
Chairman of Scientific Advisory Board10.5yrsUS$30.00ksin datos
Owen Hughes
Independent Chairman9.3yrsUS$832.23k0.034%
$ 163.1k
Catherine Friedman
Independent Director7yrsUS$556.41k0.045%
$ 215.1k
Gary Hattersley
Member of Scientific Advisory Board3.8yrsUS$1.94msin datos
6.8yrs
Permanencia media
68.5yo
Promedio de edad

Junta con experiencia: La junta directiva de RDUS se considera experimentada (6.8 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2022/08/11 10:24
Precio de las acciones al final del día2022/08/11 00:00
Beneficios2022/06/30
Ingresos anuales2021/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Radius Health, Inc. está cubierta por 12 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Gregory HarrisonBofA Global Research
John NewmanCanaccord Genuity
Mara GoldsteinCantor Fitzgerald & Co.